PONTE VEDRA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the third quarter 2025 after the close of trading on Thursday, November 6, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors inter ...

Core Insights - Treace Medical Concepts, Inc. is set to release its financial results for Q2 2025 on August 7, 2025, after market close, followed by a conference call at 4:30 pm ET to discuss the results [1] - The company specializes in medical technology aimed at improving surgical treatments for bunions and midfoot deformities, with innovative procedures like Lapiplasty and Adductoplasty [1][4] Company Overview - Treace Medical Concepts focuses on advancing surgical management standards for bunions, which affect approximately 67 million Americans, with an estimated 1.1 million being surgical candidates annually [4] - The company has developed the patented Lapiplasty® 3D Bunion Correction® System, which addresses the root cause of bunions by correcting deformities in three planes and stabilizing the affected joint [4] - Additional products include the Adductoplasty® Midfoot Correction System, SpeedMTP™ Rapid Compression Implant, and systems for minimally invasive surgeries, expanding Treace's presence in the foot and ankle market [4]